Delielena Poli’s Post

📄 New whitepaper in the Journal of Cell and Gene Therapy Insights highlights the overlooked burden of faecal incontinence (FI) and proposes cell therapy as a transformative solution. The paper discusses the potential of cell therapy to provide a minimally invasive, curative option compared to current treatments. The AMELIE project, supported by CVBF, is a notable initiative in this field. For more details, access the open-access paper. #CellTherapy #MedicalResearch #FaecalIncontinence #AMELIE 

How can the latest cell therapy technologies be harnessed to treat faecal incontinence? Read our newly published article, free to read in the Cell and Gene Therapy Insights journal: https://lnkd.in/ee_aNQYp #faecalincontinence #regenerativemedicine #celltherapy

❓Fecal incontinence is a condition that is hugely prevalent, yet underreported and stigmatized. 📄 In this article, together with colleagues from ttopstart and the AMELIE project, we hoped to raise awareness and highlight the potential of cell therapy as a potential alternative to the current therapeutic options. 👉🏼To read the full article, you can follow the link in the post below.

In this week’s Sg2 Perspectives, host Jayme Zage, PhD, is joined by Sg2 Associate Principal Justin Cassidy, PhD, to discuss what’s going on in the cell and gene therapy space. Justin talks about the increasing approvals of gene therapies and their primary barriers and challenges, as well as who should be involved in the decisions about receiving these therapies and how providers and manufacturers can gain patients’ trust. https://bit.ly/3ybfRGh

Yes, cell and gene therapy trials are extremely complex. But they’re worth it. We can help you design CGT trials in #rarediseases – download the guide here: https://lnkd.in/g4ydBRdT #CellTherapy #GeneTherapy #CGT

Are you interested in learning more about: 🦠 Overcoming challenges in the industrialisation of iPSC-derived therapies? 🏥 UK patient referral pathways for gene therapy and CAR-T? 📝 How to develop a robust Target Product Profile (TPP) for your #ATMP? Take a look at our webinar recordings to hear from the experts at CGT Catapult addressing the key topics above and many more relating to the #cell and #gene therapy industry: https://buff.ly/3uE5HLS #CellTherapy #GeneTherapy #AdvancedTherapies #Innovation #Webinars

Driven by a continued focus on personalised medicine, cell and gene therapies have experienced continued growth over the past 15 years, with the number of FDA-approved therapies more than doubling since 2020. Andrew Way from our Life Sciences team explores the main challenges associated with the rise of new therapies entering the market and how these might be tackled. Read blog > https://lnkd.in/e7EA3jN6 #mrx #lifescience #healthresearch

The Cell and Gene Therapy Catapult Annual Review details the UK ATMP industry growth and CGT Catapult impact. It also highlights the the four conditions that need to be met for the continued growth and success of the industry. Download it here - https://ow.ly/WVKr50ThbgA

#Interview now available! Creating pathways to necessary innovation in cell and #genetherapy The persistent challenges in the cell and gene therapy space need creative solutions. Nobel laureate and President Emeritus of the California Institute of Technology, David Baltimore, discusses how to successfully foster R&D innovation. Read this #article below: #immunotherapy #mrnatherapeutics #mrnavaccines #celltherapy

Catch a recap of a recent #ISCT2024 roundtable in #Vancouver moderated by Dalip Sethi, PhD, MBA - "Current State and Future Directions of #ProcessAnalyticalTechnologies in the CGT Space." #CellGeneTherapies #CellTherapy #GeneTherapy #PAT ISCT, International Society for Cell & Gene Therapy